Johnson & Johnson ESMO 2026: JNJ-6143 RIPTAC Debut, RYBREVANT FASPRO and ERLEADA Lead Solid Tumor Slate
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
Eli Lilly Sofe-M Plus Bevacizumab Delivers 79% Response Rate in Platinum-Sensitive Ovarian Cancer at ESMO 2026
Lilly Sofe-M, an investigational FRα-targeting antibody-drug conjugate, combined with bevacizumab produced a 79.3% confirmed objective response rate and 100% disease control in platinum-sensitive ovarian cancer in Phase 1 data, to be presented orally at ESMO 2026 in Madrid.
Abbott Q3 2026 Results: Abbott (NYSE: ABT) Posts 14.5% Sales Growth, Reaffirms Full-Year EPS Guidance Midpoint
Abbott Q3 2026 Results show net sales of $13.013 billion, up 14.5% reported and 7.0% comparable, with adjusted EPS of $1.42 and full-year EPS guidance tightened to $5.50 to $5.55.
Charles River FDA Collaboration With Labcorp Targets New Preclinical Methods for Abuse Potential Assessment
Charles River, Labcorp and the FDA have signed a Research Collaboration Agreement to develop sensitive preclinical tools that quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations.
Samsung Biologics Q3 2026 Results: Plant 5 Ramp-Up and Rockville Lift Revenue to KRW 1,490 Billion as 2026 Guidance Rises to 20%
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.
Amgen and AstraZeneca Report TEZSPIRE Eosinophilic Esophagitis Phase 3 CROSSING Results
TEZSPIRE Eosinophilic Esophagitis results from the Phase 3 CROSSING trial show histologic remission and dysphagia improvement at week 24, sustained through week 52, Amgen and AstraZeneca announced on October 20, 2026.
Merck KGaA Announces Silence Therapeutics Acquisition to Add Divesiran siRNA Therapy to Rare Disease Pipeline
The Silence Therapeutics acquisition gives Merck KGaA, Darmstadt, Germany, the Phase 3-ready siRNA therapy Divesiran for polycythemia vera. The deal carries a $1.1 billion enterprise value and is expected to close in Q1 2027.
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, 2026, alongside more than 90 additional abstracts.
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regeneron says the CHMP has recommended EU approval of an alternative Libtayo dosing schedule: 700 mg every six weeks after an initial 12-week regimen of 350 mg every three weeks. The opinion also supports an optional 15-30 minute infusion for eligible patients. The European Commission decision is expected in the coming months.
Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease patients reach corticosteroid-free deep remission at one year, including patients with prior biologic failure.